A new digital experience is coming
Fall 2025
. ALZpath is evolving — and so is our website.
Our Science
FAQs
About Us
News
Contact Us
Our Science
FAQs
About Us
News
Contact Us
Contact Us
Search
News
Media Inquiries:
media@alzpath.bio
July 28, 2025
Global Momentum and Validation Grows at AAIC for ALZpath Proprietary pTau217 Antibody Use in Alzheimer’s Disease Research, Diagnosis, and Treatment
Read More
April 7, 2025
ALZpath Named 2025 BRONZE Edison Award Winner for its Proprietary pTau217 Antibody, a Key Biomarker Driving Blood-Based Alzheimer’s Disease Diagnostics
Read More
April 1, 2025
Data Showcasing ALZpath’s Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer’s Disease Research and Diagnosis
Read More
March 25, 2025
ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor
Read More
March 18, 2025
ALZpath Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025
Read More
January 27, 2025
ALZpath Appoints Mike Banville as CEO
Read More
November 18, 2024
Bio-Techne and ALZpath Announce Strategic Partnership to Advance Neurodegenerative Disease Research
Read More
October 30, 2024
ALZpath Proprietary pTau217 Antibody Named to TIME’S List of the Best Inventions of 2024
Read More
July 29, 2024
New Data Presented at AAIC 2024 Demonstrates High Accuracy of Blood Tests Incorporating ALZpath Proprietary pTau217 Antibody for Alzheimer’s Disease Diagnosis
Read More
July 15, 2024
ALZpath Signs Licensing Agreement with Beckman Coulter Diagnostics to Provide Proprietary pTau217 Antibody to Develop a Diagnostic Blood Test for Alzheimer’s Disease
Read More
July 9, 2024
ALZpath Announces Appointment of Chad Holland as President and Chief Executive Officer
Read More
June 10, 2024
ALZpath Announces Licensing Agreement with Roche for Use of ALZpath’s Proprietary pTau217 Antibody in Blood Test to Diagnose Alzheimer’s Disease
Read More
February 29, 2024
Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer’s Disease Research
Read More
January 22, 2024
New Study Published in JAMA Neurology Affirms High Diagnostic Accuracy of ALZpath’s pTau217 Test in Identifying Amyloid and Tau in the Brain
Read More
July 18, 2023
ALZpath Announces New Funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to Advance a Novel, Diagnostic Blood-Based Assay
Read More
November 28, 2022
ALZpath Inc., an Alzheimer’s Disease Diagnostics and Patient Services Company Announces Novel Validated and Scalable Assay for Detection of Phosphorylated Tau 217 in Blood
Read More
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok
